

## 2020 Topical Testosterone Prior Authorization Request

Page 1 of 2

(You must complete both pages.)

Fax completed form to: 1-800-408-2386

For urgent requests, please call: 1-800-414-2386

## Coverage Criteria for Androderm patch and testosterone topical solution:

Medication is covered when being prescribed for gender dysphoria in transgender male patients or replacement therapy in male
members (or a member that self-identifies as male) for conditions associated with a deficiency or absence of endogenous testosterone
such as primary hypogonadism or hypogonadotropic hypogonadism.

## AND

- For Hypogonadism:
  - For therapy initiation: the member must have at least TWO (2) confirmed low testosterone levels according to current practice guidelines or the standard male lab reference values
  - For continuation of therapy: the member must have had a confirmed low testosterone level according to current practice guidelines or the standard male lab reference values before starting testosterone therapy.
- For gender dysphoria in transgender male patients:
  - The member must be able to make a mature, informed decision to engage in therapy

**Authorization duration**: Through end of plan contract year.

Patient information		Prescriber information				
Patient name		Today's date	Physician s		pecialty	
Patient insurance ID number		Physician name			NPI/DEA number	
Patient address, city, state, ZIP		Physician address, city, state, ZIP				
Patient home telephone number		M.D. office telephone number				
Gender  Male Female	Patient date of birth	M.D. office fax number				
Diagnosis and medical information	on					
Medication requested  Androderm transdermal patch testosterone 30mg/act solution Other:			Strength and route of administration		Frequency	
			0	D	Compared to a larger the angle of the angle of	
New prescription OR date therapy initiated			Quantity	Day supply	Expected length of therapy	
Diagnosis (Please include all office notes supporting diagnosis.)						
☐ Primary hypogonadism in adult males						
☐ Hypogonadotropic hypogonadism in adult males						
☐ Gender dysphoria in transgender male patients						
☐ Other diagnoses/ICD 10 codes:						
Please check all boxes that apply	y:					
1. Patient is stable on current drug(s) and/or current quantity, medication change would likely result in high risk of significant adverse clinical outcomes.						
2. All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.						

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.



## Page 2 of 2

Please check a	Il boxes that apply (continued):							
3.  Yes N	For INITIATION of therapy f	For INITIATION of therapy for hypogonadism in a male patient or a patient that self-identifies as male:						
	Does the patient have at leas	st two (2) confirmed low testosterone le	vels according to co	urrent practice guidelines				
	or your standard male lab ref	erence values? If yes, please provide	e TWO (2) low test	tosterone levels:				
	Testosterone Level: circle of	one (Total / Free) level	laboratory range	(low /high/ normal)				
		one (Total / Free) level laborat						
4.  Yes N	lo For CONTINUATION of ther	For CONTINUATION of therapy for hypogonadism in a male patient or a patient that self-identifies as male:						
		Does the patient have a confirmed low testosterone level according to current practice guidelines or your standard male						
		lab reference values before starting testosterone therapy? If yes, please provide ONE (1) low testosterone level:						
		one (Total / Free) level						
5.  Yes N	Is the medication requested for gender dysphoria in a transgender male patient who is able to make an informed, mature decision to engage in therapy?							
6. Yes No The quantity limit for Androderm patch is 30 patches per 30 days and the quantity limit for testosterone solution is 180 ml per 30 days.								
	Does the patient require a h	higher dosage (quantity limit excepti	on)?					
	► If <b>YES</b> , indicate quantity re	quested: per 30 days	OR quantity	per day				
☐ The	number of doses available under	the dose restriction for the prescription	drug has been inef	ffective in the treatment of the				
enrollee's disease or medical condition.								
		the dose restriction for the prescription						
medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.								
			-	it compliance.				
7. Please list all medications the patient has tried specific to the diagnosis and specify below.  CURRENT/PAST MEDICATIONS USED  DATES OF TREATMENT  THERAPEUTIC OUTCOME								
CURRENT/PAS	I MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC O	UTCOME				
8. 🗌 Other supp	porting information							
		er supporting statements. Requests tha						
utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your								
request.								
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true,								
and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is								
material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble								
	damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have							
obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.								
Prescriber signature  Date								
Prescriber sign	iatuie			'al <del>c</del>				

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.